Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2011, Vol. 31 Issue (03): 87-90    DOI:
    
The Progress of Study on Innate Immunity Led to the Design and Development of More Specific and Focused Adjuvants
SUN Ying-jun, ZHANG Yan, WU Qiong, ZHENG Hai-xue, ZHANG Zhi-dong
State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of the Ministry of Agriculture, National Foot-and-mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China
Download: HTML   PDF(486KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Recombinant DNA vaccines, subunit vaccines and synthetic peptide vaccines have sprung up one after another in recent years. These vaccines are characteristic with high purity, specificity, but they can not induce efficient immune response because of small molecule and low immunogenicity. Therefor, there is demand for safe and non-toxic adjuvants able to enhance the protective immune response. Recent advances in basic immunology have elucidated how early innate immune signals can shape subsequent adaptive responses, and this coupled with improvements in biochemical techniques, has led to the design and development of more specific and focused adjuvants.The type and mechanism of adjuvants, the progress of study on innate immunity and also explores future directions of adjuvant development are reviewed. All these could provide some references for the study on highly active, low toxicity adjuvants.



Key wordsAdjuvant      TLR      Innate immunity      Vaccine     
Received: 11 November 2010      Published: 01 April 2011
ZTFLH:  Q352  
Cite this article:

SUN Ying-jun, ZHANG Yan, WU Qiong, ZHENG Hai-xue, ZHANG Zhi-dong. The Progress of Study on Innate Immunity Led to the Design and Development of More Specific and Focused Adjuvants. China Biotechnology, 2011, 31(03): 87-90.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2011/V31/I03/87

[1] Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science, 2010, 327(5963): 291.
[2] Guy B. The perfect mix: Recent progress in adjuvant research.Nature Reviews Microbiology, 2007 , 5(7): 505-517 1740-1526.
[3] Farhat K, Riekenberg S, Heine H, et al. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. Journal of Leukocyte Biology, 2008, 83(3): 692.
[4] Letran S, Lee S, Atif S, et al. TLR5 functions as a scavenger receptor to enhance flagellin-specific CD4 T cell responses. The Journal of Immunology, 2010, 184(Meeting Abstracts 1): 136.
[5] Yarovinsky F, Zhang D, Andersen J, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science, 2005, 308(5728): 1626.
[6] McCluskie M, Krieg A. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CPG DNA. From Innate Immunity to Immunological Memory, 2006,311:155-178.
[7] Krieg A. Therapeutic potential of Toll-Like receptor 9 activation, Nature Reviews Drug Discovery, 2006, 5(6): 471-484.
[8] Boulard O, Asquith M, Powrie F, et al. TLR2-independent induction and regulation of chronic intestinal inflammation. European Journal of Immunology, 2010, 40(2): 516-524.
[9] Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature, 2006, 442(7098): 39-44.
[10] Fritz J, Le Bourhis L, Sellge G, et al. NOD1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity, 2007, 26(4): 445-459.
[11] Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature , 2006, 441(7089): 101-105.
[12] Akira, S. Innate immunity to pathogens: diversity in receptors for microbial recognition. Immunological Reviews, 2009, 227(1): 5-8.
[13] Robinson M, Sancho D, Slack E, et al. Myeloid c-type lectins in innate immunity. Nature Immunology, 2006, 7(12): 1258-1265.
[14] Klesney-Tait J, Turnbull I, Colonna M. The trem receptor family and signal integration. Nature Immunology, 2006,7(12); 1266-1273.
[15] Coffman R, Sher A, Seder R. Vaccine adjuvants: putting innate immunity to work. Immunity, 2010, 33(4): 492-503.
[16] Fritz J, Girardin S, Fitting C, et al. Synergistic stimulation of human monocytes and dendritic cells by toll-like receptor 4 and NOD1-and NOD2-activating agonists. European Journal of Immunology, 2005, 35(8): 2459-2470.
[17] Petterson T, Jendholm J, Mansson A,et al. Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-Like receptors. Journal of Leukocyte Biology,2011,89(2):177-187.

[1] XIAO Yun-xi,ZHANG Jun-he,YANG Wen-wen,CHENG Hong-wei. Research Progress of Human Diploid Cells for Vaccine Production[J]. China Biotechnology, 2021, 41(11): 74-81.
[2] ZHU Xiao-jing,WANG Rui,ZHANG Xin-xin,JIN Jia-xin,LU Wen-long,DING Da-shun,HUO Cui-mei,LI Qing-mei,SUN Ai-jun,ZHUANG Guo-qing. Construction of MDV Recombinant Vaccine Strain Integrated F Gene Using Bacterial Artificial Chromosome Technique[J]. China Biotechnology, 2021, 41(10): 33-41.
[3] CHENG Xu,YANG Yu-qing,WU Sai-nan,HOU Qin-long,LI Yong-mei,HAN Hui-ming. Construction of DNA Vaccines of Staphylococcus aureus SarA, IcaA and Their Fusion Genes and Preliminary Study in Mouse Immune Response[J]. China Biotechnology, 2020, 40(7): 41-50.
[4] GUO Yang,WAN Ying-han,WANG Jue,GONG Hui,ZHOU Yu,CI Lei,WAN Zhi-peng,SUN Rui-lin,FEI Jian,SHEN Ru-ling. Toll-like Receptor 4 (TLR4) Gene Knockout Mouse Model Construction and Preliminary Phenotypic Analysis[J]. China Biotechnology, 2020, 40(6): 1-9.
[5] LIU Zhen-zhen,TIAN Da-yong. Development of Sucrose Density Gradient Centrifugation Purification Process for Rabies Vaccine[J]. China Biotechnology, 2020, 40(4): 25-33.
[6] QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing. Application of Adjuvant in Cancer Immunotherapy[J]. China Biotechnology, 2020, 40(3): 96-103.
[7] XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.
[8] JING Hui-yuan,DUAN Er-zhen,DONG Wang. In Vitro Transcribed Self-amplifying mRNA Vaccines[J]. China Biotechnology, 2020, 40(12): 25-30.
[9] LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.
[10] FENG Xue-jiao,HOU Hai-long,YU Qiong,WANG Jun-shu. Market Analysis and Countermeasures of Cervical Cancer Vaccine in China[J]. China Biotechnology, 2020, 40(11): 96-101.
[11] Yan GAO,Jing-jing DU,Bin WANG,Qi LIU,Zhi-qiang SHEN. Study on β-Propiolactone in Inactivation Process of Rabies Vaccine by Gas Chromatography[J]. China Biotechnology, 2019, 39(6): 25-31.
[12] Lin YANG,Zhe-yan FU,Zheng-bing LV,Jian-hong SHU. Classification and Mechanism of Immune Adjuvant[J]. China Biotechnology, 2019, 39(5): 114-119.
[13] Jia-yue XU,Zi-qian LI,Ge ZHANG. Advanced in Research Dengue Virus 3'UTRΔ30 Series Vaccines[J]. China Biotechnology, 2019, 39(3): 97-104.
[14] Fu-lan GAO,Jia-long QI,Cong-yan SHU,Hang-hang XIE,Wei-wei HUANG,Cun-bao LIU,Xu YANG,Wen-jia SUN,Hong-mei BAI,Yan-bing MA. Efficient Secretory Expression of Optimized Mouse Interleukin-33 Gene in Mammalian Cells[J]. China Biotechnology, 2019, 39(3): 46-55.
[15] Xi-wen JIANG,Zi-wei DONG,Yue LIU,Xiao-ya ZHU. Reserch Progress on Biomarkers and Precision Medicine[J]. China Biotechnology, 2019, 39(2): 74-81.